Autor: "Brashear HR" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer’s disease [Corrigendum]
Autorzy:: Hager K
Baseman AS
Nye JS
Brashear HR
Han J
Sano M
Davis B
Richards HM; Pokaż więcej
Temat:: Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
Źródło:: Neuropsychiatric Disease and Treatment, Vol 2014, Iss default, Pp 1997-1998 (2014)
Opis pliku:: electronic resource
Relacje:: http://www.dovepress.com/corrigendum-effects-of-galantamine-in-a-2-year-randomized-placebo-peer-reviewed-article-NDT; https://doaj.org/toc/1178-2021
Dostęp URL:: https://doaj.org/article/09ce8a88547845a3adad92e246cc5c0a Link otwiera się w nowym oknie

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 2.

Informacja:: Dostęp do tej pozycji wymaga zalogowania się.

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 3.

Informacja:: Dostęp do tej pozycji wymaga zalogowania się.

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 4.

Informacja:: Dostęp do tej pozycji wymaga zalogowania się.

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 5.

Informacja:: Dostęp do tej pozycji wymaga zalogowania się.

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 6.

Informacja:: Dostęp do tej pozycji wymaga zalogowania się.

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 7.

Informacja:: Dostęp do tej pozycji wymaga zalogowania się.

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 8.

Informacja:: Dostęp do tej pozycji wymaga zalogowania się.

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 9.

Tytuł:: Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer's disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study.
Autorzy:: Novak G; Janssen Research and Development LLC, 1125 Trenton-Harbourton Rd, Titusville, NJ, 08560, USA. .
Streffer JR; Janssen Research and Development, a Division of Janssen Pharmaceutica NV, Beerse, Belgium.; Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.; Present address: UCB Biopharma SPRL, Chemin du Foriest, B-1420, Braine-l'Alleud, Belgium.
Timmers M; Janssen Research and Development, a Division of Janssen Pharmaceutica NV, Beerse, Belgium.; Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.
Henley D; Janssen Research and Development LLC, 1125 Trenton-Harbourton Rd, Titusville, NJ, 08560, USA.
Brashear HR; Janssen Research and Development LLC, 1125 Trenton-Harbourton Rd, Titusville, NJ, 08560, USA.
Bogert J; Janssen Research and Development LLC, Raritan, NJ, USA.
Russu A; Janssen Research and Development, a Division of Janssen Pharmaceutica NV, Beerse, Belgium.
Janssens L; Janssen Research and Development, a Division of Janssen Pharmaceutica NV, Beerse, Belgium.
Tesseur I; Janssen Research and Development, a Division of Janssen Pharmaceutica NV, Beerse, Belgium.; Present address: UCB Biopharma SPRL, Chemin du Foriest, B-1420, Braine-l'Alleud, Belgium.
Tritsmans L; Janssen Research and Development, a Division of Janssen Pharmaceutica NV, Beerse, Belgium.
Van Nueten L; Janssen Research and Development, a Division of Janssen Pharmaceutica NV, Beerse, Belgium.
Engelborghs S; Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.; Department of Neurology and Center for Neurosciences, UZ Brussel and Vrije Universiteit Brussel (VUB), Brussels, Belgium.; Pokaż więcej
Źródło:: Alzheimer's research & therapy [Alzheimers Res Ther] 2020 May 14; Vol. 12 (1), pp. 58. Date of Electronic Publication: 2020 May 14.
Typ publikacji:: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:: Alzheimer Disease*/drug therapy
Amyloid Precursor Protein Secretases*
Amyloid beta-Peptides ; Aspartic Acid Endopeptidases ; Double-Blind Method ; Humans ; Pyridines ; Thiazines ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 10.

Tytuł:: Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Bapineuzumab: A Single-Ascending-Dose Study in Patients With Mild to Moderate Alzheimer Disease.
Autorzy:: Lu M; Janssen Alzheimer's Immunotherapy Research & Development, Spring House, PA, USA.
Brashear HR; Janssen Alzheimer's Immunotherapy Research & Development, Spring House, PA, USA.; Pokaż więcej
Źródło:: Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2019 Apr; Vol. 8 (3), pp. 326-335. Date of Electronic Publication: 2018 Jun 19.
Typ publikacji:: Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:: Antibodies, Monoclonal, Humanized*/adverse effects
Antibodies, Monoclonal, Humanized*/blood
Antibodies, Monoclonal, Humanized*/therapeutic use
Nootropic Agents*/adverse effects
Nootropic Agents*/blood
Nootropic Agents*/therapeutic use
Alzheimer Disease/*drug therapy
Aged ; Aged, 80 and over ; Alzheimer Disease/psychology ; Amyloid beta-Peptides/blood ; Cognition/drug effects ; Cohort Studies ; Dose-Response Relationship, Drug ; Double-Blind Method ; Half-Life ; Humans ; Injections, Subcutaneous ; Middle Aged ; Severity of Illness Index ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 11.

Tytuł:: Effect of concomitant use of memantine on mortality and efficacy outcomes of galantamine-treated patients with Alzheimer's disease: post-hoc analysis of a randomized placebo-controlled study.
Autorzy:: Hager K; Clinic for Medicine of the Elderly, Hannover, Germany.
Baseman AS; Janssen Research and Development, LLC, Titusville, NJ, USA. .; Janssen Research and Development, LLC, 850 Ridgeview Drive, Horsham, PA, 19044, USA. .
Nye JS; Janssen Research and Development, LLC, Titusville, NJ, USA.
Brashear HR; Janssen Research and Development, LLC, Titusville, NJ, USA.
Han J; Janssen Research and Development, LLC, Titusville, NJ, USA.
Sano M; The Mount Sinai Medical Center, New York, NY, USA.
Davis B; Synaptec Inc, Palm Beach Gardens, FL, USA.
Richards HM; Janssen Research and Development, LLC, Titusville, NJ, USA.; Pokaż więcej
Źródło:: Alzheimer's research & therapy [Alzheimers Res Ther] 2016 Nov 15; Vol. 8 (1), pp. 47. Date of Electronic Publication: 2016 Nov 15.
Typ publikacji:: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:: Alzheimer Disease*/drug therapy
Alzheimer Disease*/mortality
Alzheimer Disease*/psychology
Treatment Outcome*
Cholinesterase Inhibitors/*therapeutic use
Excitatory Amino Acid Antagonists/*therapeutic use
Galantamine/*therapeutic use
Memantine/*therapeutic use
Aged ; Aged, 80 and over ; Disability Evaluation ; Double-Blind Method ; Female ; Humans ; Longitudinal Studies ; Male ; Middle Aged ; Psychiatric Status Rating Scales ; Retrospective Studies

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 12.

Tytuł:: Long-term safety and tolerability of bapineuzumab in patients with Alzheimer's disease in two phase 3 extension studies.
Autorzy:: Ivanoiu A; Université Catholique de Louvain, Cliniques Universitaires Saint-Luc, 10 Avenue Hipocrate, B-1200, Bruxelles, Belgium. .
Pariente J; Centre d'investigation Clinique, Centre Mémoire et Langage, Service de Neurologie, CHU Purpan, Place du Dr Baylac, 31059, Toulouse, France.
Booth K; Pfizer Inc., 500 Arcola Road, Collegeville, PA, 19426, USA.
Lobello K; Pfizer Inc., 500 Arcola Road, Collegeville, PA, 19426, USA.
Luscan G; Pfizer PGRD, 23-25 avenue du Docteur Lannelongue, 75668, Paris cedex 14, France.
Hua L; Pfizer Inc., 500 Arcola Road, Collegeville, PA, 19426, USA.
Lucas P; Pfizer PGRD, 23-25 avenue du Docteur Lannelongue, 75668, Paris cedex 14, France.
Styren S; Pfizer Inc., Eastern Point Road, Groton, CT, 06340, USA.
Yang L; Pfizer Inc., 500 Arcola Road, Collegeville, PA, 19426, USA.
Li D; Pfizer Inc., 500 Arcola Road, Collegeville, PA, 19426, USA.
Black RS; Pfizer Inc., 500 Arcola Road, Collegeville, PA, 19426, USA.
Brashear HR; Janssen Alzheimer Immunotherapy Research & Development, LLC, 700 Gateway Blvd., South San Francisco, CA, 94080, USA.
McRae T; Pfizer Inc., 235 East 42nd Street, New York, NY, 10017, USA.; Pokaż więcej
Źródło:: Alzheimer's research & therapy [Alzheimers Res Ther] 2016 Jun 23; Vol. 8 (1), pp. 24. Date of Electronic Publication: 2016 Jun 23.
Typ publikacji:: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:: Alzheimer Disease/*drug therapy
Antibodies, Monoclonal, Humanized/*adverse effects
Antibodies, Monoclonal, Humanized/*therapeutic use
Aged ; Alzheimer Disease/immunology ; Antibodies, Monoclonal, Humanized/genetics ; Apolipoproteins E/genetics ; Female ; Humans ; Male ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 13.

Tytuł:: Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials.
Autorzy:: Vandenberghe R; University Hospitals Leuven, Department of Neurosciences, Alzheimer Research Centre KU Leuven, Herestraat 49, 3000, Leuven, Belgium. .
Rinne JO; Turku PET Centre and Division of Clinical Neurosciences, University of Turku and Turku University Hospital, Kiinamyllynkatu 4-8, 20520, Turku, Finland.
Boada M; Fundació ACE, Barcelona Alzheimer Treatment and Research Center, Gran via de Carles III, 85 Bis, 08028, Barcelona, Spain.
Katayama S; Graduate School of Biomedical Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
Scheltens P; Alzheimercentrum VUmc, Neurology, VU University Medical Center, PO Box 7057, 1007, MB, Amsterdam, Netherlands.
Vellas B; CHU Toulouse, Gérontopôle, 170 Avenue de Casselardit, TSA 40031, 31059, Toulouse, Cedex 9, France.
Tuchman M; Palm Beach Neurological Center, 3365 Burns Road, Suite 203, Palm Beach Gardens, FL, 33410, USA.
Gass A; Department of Neurology, University Hospital Mannheim, University Medical Centre Mannheim, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.
Fiebach JB; Center for Stroke Research Berlin (CSB), Charité Universitätsmedizin Berlin, Hindenburgdamm 30, 12200, Berlin, Germany.
Hill D; IXICO Ltd., The London Bioscience Innovation Centre, 4th Floor, Griffin Court, 15 Long Lane, London, EC1A 9PN, UK.
Lobello K; Pfizer Inc., 500 Arcola Road, Collegeville, PA, 19426, USA.
Li D; Pfizer Inc., 500 Arcola Road, Collegeville, PA, 19426, USA.
McRae T; Pfizer Inc., 235 East 42nd Street, New York, NY, 10017, USA.
Lucas P; Pfizer Global Research and Development (PGRD), 23-25 avenue Du Docteur Lannelongue, Paris, Île-De-France, 75014, France.
Evans I; Pfizer Ltd., Walton Oaks, Dorking Road, Tadworth, Surrey, KT20 7NS, UK.
Booth K; Pfizer Inc., 500 Arcola Road, Collegeville, PA, 19426, USA.
Luscan G; Pfizer Global Research and Development (PGRD), 23-25 avenue Du Docteur Lannelongue, Paris, Île-De-France, 75014, France.
Wyman BT; Pfizer Inc., 7 Kings Highway, Groton, CT, 06340, USA.
Hua L; Pfizer Inc., 500 Arcola Road, Collegeville, PA, 19426, USA.
Yang L; Pfizer Inc., 500 Arcola Road, Collegeville, PA, 19426, USA.
Brashear HR; Janssen Alzheimer Immunotherapy Research & Development, LLC, 700 Gateway Boulevard, South San Francisco, CA, 94080, USA.
Black RS; Pfizer Inc., 500 Arcola Road, Collegeville, PA, 19426, USA.; Pokaż więcej
Corporate Authors:: Bapineuzumab 3000 and 3001 Clinical Study Investigators
Źródło:: Alzheimer's research & therapy [Alzheimers Res Ther] 2016 May 12; Vol. 8 (1), pp. 18. Date of Electronic Publication: 2016 May 12.
Typ publikacji:: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:: Alzheimer Disease/*drug therapy
Antibodies, Monoclonal, Humanized/*therapeutic use
Aged ; Alzheimer Disease/diagnostic imaging ; Alzheimer Disease/genetics ; Alzheimer Disease/metabolism ; Amyloid beta-Peptides/metabolism ; Apolipoprotein E4/genetics ; Biomarkers/cerebrospinal fluid ; Biomarkers/metabolism ; Brain/diagnostic imaging ; Brain/metabolism ; Female ; Humans ; Male ; Neuropsychological Tests ; Positron-Emission Tomography ; Severity of Illness Index ; Treatment Outcome ; tau Proteins/cerebrospinal fluid

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 14.

Tytuł:: First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer's disease.
Autorzy:: Delnomdedieu M; Pfizer Neuroscience Research Unit, Cambridge, MA, USA. .
Duvvuri S; Pfizer Neuroscience Research Unit, Cambridge, MA, USA. .
Li DJ; Pfizer Neuroscience Research Unit, Cambridge, MA, USA. .
Atassi N; Mass General Hospital, Boston, MA, USA. .
Lu M; Janssen R&D, Spring House, PA, USA. .
Brashear HR; Janssen R&D, Fremont, CA, USA. .
Liu E; Janssen R&D, Fremont, CA, USA. .
Ness S; Janssen R&D, Fremont, CA, USA. .
Kupiec JW; Pfizer Neuroscience Research Unit, Cambridge, MA, USA. .; Pokaż więcej
Źródło:: Alzheimer's research & therapy [Alzheimers Res Ther] 2016 Mar 01; Vol. 8 (1), pp. 12. Date of Electronic Publication: 2016 Mar 01.
Typ publikacji:: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:: Alzheimer Disease/*blood
Alzheimer Disease/*drug therapy
Amyloid beta-Peptides/*blood
Amyloid beta-Peptides/*immunology
Antibodies, Monoclonal, Humanized/*adverse effects
Antibodies, Monoclonal, Humanized/*therapeutic use
Brain Edema/*chemically induced
Aged ; Alzheimer Disease/cerebrospinal fluid ; Alzheimer Disease/immunology ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antibodies, Monoclonal, Humanized/pharmacokinetics ; Biomarkers/blood ; Dose-Response Relationship, Drug ; Female ; Humans ; Infusions, Intravenous ; Male ; Middle Aged ; Severity of Illness Index